Takeda Pharmaceutical (NYSE:TAK) Upgraded at Zacks Research

Zacks Research upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday,Zacks.com reports.

Several other research analysts have also recently commented on TAK. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Finally, Morgan Stanley initiated coverage on shares of Takeda Pharmaceutical in a report on Tuesday, January 13th. They set an “overweight” rating for the company. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold”.

Takeda Pharmaceutical Trading Down 2.6%

Shares of TAK opened at $17.75 on Tuesday. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $18.82. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $56.48 billion, a price-to-earnings ratio of 73.96 and a beta of 0.01. The stock’s 50-day moving average price is $17.16 and its 200 day moving average price is $15.44.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 29th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.40. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%.The company had revenue of $6.75 billion during the quarter, compared to the consensus estimate of $7.81 billion. As a group, research analysts predict that Takeda Pharmaceutical will post 1.64 earnings per share for the current year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Private Trust Co. NA increased its position in shares of Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after acquiring an additional 783 shares in the last quarter. Twin Peaks Wealth Advisors LLC acquired a new position in Takeda Pharmaceutical in the 2nd quarter worth $28,000. Evelyn Partners Investment Management LLP increased its holdings in Takeda Pharmaceutical by 163.4% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock worth $39,000 after purchasing an additional 1,560 shares in the last quarter. True Wealth Design LLC increased its holdings in Takeda Pharmaceutical by 1,262.3% during the 3rd quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock worth $40,000 after purchasing an additional 2,512 shares in the last quarter. Finally, Parkside Financial Bank & Trust raised its stake in shares of Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after purchasing an additional 1,684 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.